CCNA2 and ovarian cancer: For example, CCNA2 mRNA levels were found to be decreased significantly with fold change -1.07, -4.33, -1.06, and -4.17 when treated with romidepsin, SNAO32, dauricine, and doxorubicin in A549, primary ovarian cancer, BxPC3, and MCF7 cell lines, respectively.